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Background and Purpose   
Although atrial fibrillation (AF) patients who suffered an acute stroke are at high risk for 
recurrence, many patients are untreated or treated suboptimally for stroke prevention. 
To compare clinical outcomes of AF patients with versus without previous stroke in relation 
to guideline-adherent antithrombotic treatment (ATT) in a contemporary primary care 
population.  
Methods  
Community cohort of 105,000 patients from 11 general practices in Darlington, England was 
used to assess AF stroke prevention strategies against 2014 National Institute for Health and 
Care Excellence (NICE) guidelines.  
Results   
Overall, 2259 (2.15%) AF patients were identified, of which 18.9% constituted a secondary 
prevention cohort. For secondary prevention, ATT was guideline-adherent in 56.3%, 18.9% 
were over-treated and 24.8% under-treated; corresponding proportions for primary prevention 
were 49.5%, 11.7% and 38.8%, respectively.  
One-year stroke rates were 8.6% and 1.6% for secondary and primary prevention, 
respectively (p<0.001); corresponding all-cause mortality rates were 9.8% and 9.4%, 
respectively (p=0.79).  
On multivariable analysis, lack of ATT guideline adherence was associated with increased 
stroke risk for primary prevention (OR 2.95, 95% CI 1.26-6.90, p=0.013 for under-
treatment); for secondary prevention, lack of guideline adherence was associated with 
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increased risk of recurrent stroke (OR 2.80, 95% CI 1.25-6.27, p=0.012 for over-treatment) 
and all-cause death (OR 2.75, 95% CI 1.33-5.69, p=0.006 for under-treatment).  
Conclusions    
Only approximately half of eligible AF patients are prescribed OAC in line with guidelines.  
Guideline-adherent ATT significantly reduces the risk of stroke amongst primary prevention 
patients, and both risk of recurrent stroke and death in patients with previous stroke. 
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One third of ischemic strokes and over 80% of cardioembolic strokes are related to atrial 
fibrillation (AF).1 AF may also play a role in approximately a third of cryptogenic strokes, 
which account for 25% of all strokes.2 AF-related strokes result in a larger area of brain 
infarction and greater disability and mortality compared to strokes of other etiologies.3 
However, AF remains frequently under-recognized in patients who suffer an acute stroke and 
it is often left untreated in those with recent AF-related stroke, despite high risk for stroke 
recurrence.1  
 
AF-related strokes are highly preventable. A meta-analysis showed that oral anticoagulation 
(OAC) with vitamin K antagonists (VKAs), such as warfarin, reduces the risk of stroke in AF 
patients by 64% and mortality by 26%, compared to placebo, whereas aspirin did not 
significantly decrease stroke risk and had no impact on mortality.4 Another meta-analysis 
demonstrated that non-VKA OACs (NOACs) may offer additional stroke and mortality risk 
reduction by 19% and 10% respectively, relative to warfarin.5 Consequently, in line with 
current AF guidelines, OAC should be offered to all AF patients as a default practice unless a 
“truly low-risk” category is evident, i.e. those with a CHA2DS2-VASc score=0 for men or 
CHA2DS2-VASc=1 for women.
6  
 
Despite these recommendations, contemporary registry data show that more than half of AF 
patients with no stroke risk factors are anticoagulated, while at least a third of those at high 
risk of stroke do not receive OAC where indicated, but instead are prescribed antiplatelet 
monotherapy or remain untreated.7 Importantly, lack of guideline adherence in antithrombotic 
treatment for stroke prevention in AF has been shown to increase stroke/thromboembolic and 
mortality rates compared to recommended therapy.8–11 
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In contrast to previous data on guideline-adherence for stroke prevention in AF 
predominantly implemented by cardiologists,7–10 we present findings from 11 general 
practices in the United Kingdom (UK) serving the community cohort of 105,000 patients, of 
whom 2.15% (n=2259) had established AF diagnosis. Our objective was to assess clinical 
outcomes of community-based AF patients with versus without previous stroke in relation to 
guideline-adherent antithrombotic treatment for stroke prevention. 
 
Materials and Methods  
Study Population 
The design of the Darlington AF Registry has been described previously.12  In brief, the study 
population comprised of 105,000 patients living in Darlington, County Durham, UK, 
registered at one of 11 general practices. All patients with the diagnosis of AF or atrial flutter 
and known vital status in March 2013 were eligible for inclusion. 
Data Collection 
Guidance on Risk Assessment and Stroke Prevention in Atrial Fibrillation (GRASP-AF) tool 
was used to collect data.12,13 All general practices in Darlington were equipped with this 
electronic record interrogation software that allowed for data collection on demographics, 
details of AF diagnosis, patient stroke risk profile and antithrombotic treatment, and was 
primarily developed to facilitate decision making on stroke prevention therapies. 
As the GRASP-AF tool does not collect data on clinical outcomes, separate searches of the 
database were performed to identify those patients who suffered acute stroke or died within 
12 months. The Read Codes were used to identify different types of strokes, comorbidities, 
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current therapies and contraindications to treatment. All clinical events were manually 
reviewed and adjudicated.12 
Definitions 
Thromboembolic risk was assessed using the CHA2DS2-VASc score (congestive heart 
failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack [TIA], 
vascular disease, age 65-74 years, sex category [female]).14 
“Low-risk” patients were men with CHA2DS2-VASc=0 and women with CHA2DS2-VASc=1 
(1 point for sex category only); “moderate-risk” were men with CHA2DS2-VASc=1; and 
“high-risk” were those with CHA2DS2-VASc score ≥2, irrespective of gender. 
Antithrombotic treatment for stroke prevention was assessed against 2014 National Institute 
for Health and Care Excellence (NICE) guidelines.6 Antithrombotic treatment was considered 
guideline-adherent when the following criteria were applicable: 
 OAC in moderate to high-risk patients with no reported contraindications to OAC 
therapy 
 no OAC in low-risk patients and those who refused treatment with OAC 
 OAC + antiplatelet therapy in moderate to high-risk patients and acute vascular 
disease (i.e. recent acute myocardial infarction) 
Lack of guideline adherence in antithrombotic treatment was considered as either over-
treatment (OAC overuse) or under-treatment (OAC underuse). Specifically, under-treatment 
was defined as no OAC (but antiplatelet or no therapy) in moderate or high-risk patients and 
no reported contraindications or refusal to treatment. Over-treatment was defined as follows: 
OAC in low-risk patients or OAC + antiplatelet therapy in moderate to high-risk patients with 
no evidence of acute vascular disease (i.e. recent acute myocardial infarction); OAC in 
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patients with reported contraindications to anticoagulation; or antiplatelet agents in those who 
had reported contraindications to both OAC and antiplatelet therapy.  
 
Of note, the American Heart Association/American College of Cardiology/Heart Rhythm 
Society guidelines differ with NICE recommendations on stroke risk requiring 
anticoagulation, i.e. OAC is recommended in patients with CHA2DS2-VASc score ≥2, while 
those with score 1 may be offered OAC, aspirin or even no stroke prophylaxis.15 
 
Statistical Analysis 
Categorical variables are presented as numbers and percentages, and continuous parameters 
as mean and standard deviation (SD). Baseline characteristics, antithrombotic therapies and 
clinical outcomes were tabulated in relation to prior stroke history. Multivariable logistic 
regression analyses were performed to determine independent predictors for new/recurrent 
stroke and all-cause death after adjustment for the components of the CHA2DS2-VASc score 
(age assessed as a continuous variable) and guideline-adherent or non-adherent (over-
treatment or under-treatment), antithrombotic treatment and AF duration. The multivariable 
analysis was performed separately for patients with prior stroke history (secondary 
prevention group) and those without previous stroke (primary prevention group). All 
statistical analyses were performed using IBM SPSS Statistics (version 21) software 
(Chicago, Illinois, USA). Statistical significance was set at a two-sided p-value of <0.05. 
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Results 
Overall, 2259 (2.15%) AF patients were identified, of which 428 (18.9%) constituted a 
secondary prevention cohort. Patients with previous stroke were older, more often had 
comorbidities and were at higher risk of stroke (all patients had CHA2DS2-VASc score ≥2, 
mean score of 5.5, standard deviation [SD] of 1.28) as compared with those without prior 
stroke (CHA2DS2-VASc score ≥2 in 82.3%, mean score of 3.0, SD of 1.54) (Table 1). 
 
Overall, <50% of patients were prescribed anticoagulation (46.4% VKAs and 1.4% NOACs), 
while 35.9% received antiplatelet therapy alone and 16.2% remained untreated (Table 1). 
Antithrombotic drug choice in relation to prior stroke history is summarized in Figure 1. 
Guideline-adherent antithrombotic treatment for stroke prevention was applied more 
frequently in the secondary versus primary prevention cohort (56.3% vs 49.5%, p=0.011). 
Over-treatment was more common in patients with prior stroke, whereas under-treatment was 
more frequent in subjects with no stroke history (Table 1, Figure 2). 
 
Based on the Read Codes, general practitioners (GPs) reported contraindications to OAC 
therapy more frequently in patients with previous stroke (13.8%) compared to subjects 
without prior stroke (7.0%) (Table I, please see http://stroke.ahajournals.org). 
 
One-Year Outcomes 
After 12 months of follow-up the observed stroke rates were 8.6% (n=37) and 1.6% (n=30) 
for the secondary and primary prevention cohort, respectively (p<0.001). No difference was 
observed in the incidence of hemorrhagic strokes (0.2% in both groups) (Table 2). All-cause 
death rates were comparable in patients with prior stroke (9.8%, n=42) and those without 
previous stroke (9.4%, n=172). The causes of death were also similar in both groups, except 
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that in the secondary prevention cohort more patients died of non-cerebral bleeding (0.5%, 
n=2) compared with the primary prevention cohort (0.1%, n=1) (Table 2). 
 
Clinical Outcomes in Relation to Guideline-Adherent Antithrombotic Therapy 
In the primary prevention group, the 1-year stroke rates were similar in guideline-adherent 
(0.8%) and over-treated patients (0.5%), while the under-treated patients had an 
approximately four-fold higher stroke rate (3.1%). The corresponding event rates for 12-
month all-cause mortality were 7.1%, 6.0% and 13.2%, respectively (Table 3). 
 
In the secondary prevention cohort, the lowest rate of stroke recurrence, at 5.4%, was in 
patients receiving guideline recommended treatment, whereas the event rates for under- and 
over-treatment were 9.4% and 17.3%, respectively (p=0.011). There was no significant 
difference in all-cause mortality between guideline-adherent (6.6%) and over-treated patients 
(6.2%, p=0.88), while the mortality was 3-fold higher in the under-treated subjects (19.8%, 
p<0.001). 
 
On multivariable logistic regression analysis (Table 4), non-adherence with guideline 
recommended antithrombotic treatment was associated with an increased risk of stroke in the 
primary prevention cohort (odds ratio [OR] 2.95, 95% confidence interval [CI] 1.26-6.90, 
p=0.013 for under-treatment), whereas in the secondary prevention cohort, non-adherence 
with guideline recommended antithrombotic treatment was associated with an increased risk 
of recurrent stroke (OR 2.80, 95% CI 1.25-6.27, p=0.012 for over-treatment) and all-cause 
death (OR 2.75, 95% CI 1.33-5.69, p=0.006 for under-treatment). No association was found 
between AF duration and outcome events.  
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As a sensitivity analysis, the impact of OAC therapy per se on clinical outcomes after 
completely excluding patients who denied treatment or had any contraindications is shown in 
the Supplementary Material (Table II and III, please see http://stroke.ahajournals.org).  The 
results show broadly similar trends as our principal analysis, with an even more pronounced 
effect of OAC on outcomes. 
 
Discussion 
 
In this paper we provide antithrombotic treatment patterns in an unselected (i.e. consecutive 
all-comers) contemporary, community-based AF population. The main findings of this study 
are that despite a high thromboembolic risk, particularly amongst secondary prevention 
patients, only approximately 50% of AF patients in primary care were prescribed OAC in line 
with guidelines. Secondly, guideline-adherent antithrombotic treatment reduces the risk of 
stroke amongst primary prevention patients, and in those with prior stroke, there was a 
significant reduction in both recurrent stroke and mortality. 
 
Several studies have found that guideline-adherent thromboprophylaxis in AF is associated 
with fewer stroke and lower mortality rates compared to non-guideline stroke prevention.8–11 
However, these studies assessed adherence to guidelines in patients managed solely by 
cardiologists8–10 or internal medicine specialists.11 Unlike in previous studies we present 
findings from a community-based AF cohort managed by primary care physicians, however it 
should be noted that the vast majority of strokes are diagnosed and managed in a hospital 
setting and specialist input is provided at that stage, unless AF was not present at the time of 
the event. Our analysis also provides novel data on the clinical implications of non-adherence 
with recommended antithrombotic treatment for stroke prevention in AF and how this affects 
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clinical outcomes in patients who have already suffered an acute stroke. 
 
As expected, we observed higher one-year stroke rates in AF patients with versus without 
prior stroke. The magnitude of the stroke rate difference was six-fold higher in secondary 
versus primary prevention patients, thereby reflecting a very high thromboembolic risk 
among those with a previous stroke. Despite such high risk only about half of the patients 
with prior strokes were prescribed OAC in line with current NICE guidelines.6 
 
More importantly, the lowest stroke recurrence was observed in patients who were guideline-
adherent, while it was higher for under-treatment and unexpectedly highest for over-
treatment. Although higher stroke rates for over-treatment compared to guideline-adherence 
may be surprising, the EORP-AF (EURObservational Research Programme Atrial 
Fibrillation) Pilot Registry also found a similar association between over-treatment and 
higher one-year incidence of thromboembolic events, defined as any of the following: stroke, 
TIA, acute coronary syndrome, coronary intervention, cardiac arrest, peripheral embolism or 
pulmonary embolism.10 By contrast, other studies have not reported such an association8,11 or 
have found a lower risk of thromboembolism for over-treatment.9 
 
The possible explanation of “more is not better” is not straightforward and may include 
various contributing factors. First, in contrast to the present analysis, none of other studies 
considered the presence of contraindications to ATT or patient’s declining therapy when 
defining adherence versus non-adherence to antithrombotic treatment.8–11 Prior papers base 
OAC prescribing solely on thromboembolic risk (and thus, this assumes that 100% must be 
given OAC, no exceptions). Such an approach fails again to reflect real-life everyday clinical 
practice, by not taking into account an unselected population of consecutive patients as well 
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as many clinical- and patient-related factors affecting the final decision-making needed for 
OAC prescribing. In addition, only the present study and the EORP-AF registry corrected the 
definition of non-adherence for the presence of acute vascular disease.10  
 
Second, although Gorin et al.9 found significantly fewer event rates in over-treated patients 
and suggested that a more aggressive antithrombotic treatment (i.e. combination of OAC and 
antiplatelet therapy) may be advocated in selected AF patients, the authors used the older 
CHADS2 score (Congestive Heart Failure, Hypertension, Age≥75, Diabetes, Stroke/TIA) 
which resulted in classifying some patients as “low-risk” (i.e. with CHADS2=0) and thus 
over-treated, while in the present analysis many of them would be categorized as “high-risk” 
and consequently guideline-adherent. In addition, over-treated patients were significantly 
younger and had lower risk of stroke compared with those under-treated or guideline-
adherent.9 By contrast, in the present analysis over-treated versus guideline-adherent patients 
were at significantly lower risk of stroke in the primary prevention, while an opposite relation 
with a trend towards a higher thromboembolic risk was noted in the over-treated, secondary 
prevention cohort. 
 
Third, unlike previous studies, we analyzed the population of AF patients with prior stroke, 
which are at the highest risk for stroke recurrence; 8.6% after one year of observation despite 
antithrombotic treatment. Indeed, our analysis did not show over-treatment to be associated 
with increased stroke rates in patients without prior stroke. Also, some physicians may 
consider that combination therapy (OAC + antiplatelets) was more effective and superior to 
OAC monotherapy for stroke prevention in patients with prior stroke. Our data suggest that 
despite such an “aggressive” antithrombotic treatment, the risk of stroke recurrence remains 
high. On the other hand, we may speculate that fear of bleeding complications while being 
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more aggressive with antithrombotic treatment results in suboptimal quality of 
anticoagulation. Indeed, for AF patients undergoing percutaneous coronary interventions and 
thus requiring combination OAC and antiplatelet therapy, the average time in therapeutic 
range (TTR) was only 52.6%, with an International Normalized Ratio (INR) of 1.6 to 2.6.16 
Consequently, instead of a decrease in stroke rates, an increase in both stroke and major 
bleeding rates were observed when compared to patients who were not receiving combination 
antithrombotic treatment.  
 
Nonetheless, despite stroke rates being three times higher in the over-treated versus 
guideline-adherent group, we have observed similar mortality rates in both treatment cohorts. 
This finding would suggest that even though a more aggressive antithrombotic regimen is not 
sufficient to protect against stroke recurrence in at very high risk of stroke AF patients, while 
many of these strokes are not fatal, reduction in all-cause mortality with antithrombotic 
therapy exceeds the reduction of stroke-related deaths only.17  
 
Despite being at very high risk for stroke, some patients may have genuine contraindications 
to anticoagulation, as many stroke and bleeding risk factors do overlap.18 In the present 
analysis, contraindications to OAC were reported in 13.8% and 7.0% of patients with versus 
without previous stroke, respectively. However, contraindications to OAC therapy are 
frequently not absolute and may be transient, and depend on individually-perceived lack of 
benefit from OAC prescription.6 Indeed, a considerable variation in the rates of reported 
contraindications to OAC (ranging from 2.6% to 12.0%) was observed across 1857 general 
practices in England.13 Contemporary registry data also show that approximately 50% of 
eligible AF patients are not offered OAC or have stroke prevention treatment discontinued 
due to physician’s preference.19,20 Many physicians have concerns with regard to prescribing 
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OAC to frail, elderly patients with many comorbidities, cognitive impairment and frequent 
falls21 although the available data show that even these patients, including the very elderly 
(>85 years of age) also benefit from anticoagulation.22,23  
 
Bleeding risk assessment scores, such as the HAS-BLED (hypertension, abnormal renal and 
liver function, stroke, bleeding, labile INR ratios, age ≥65 years, drugs or alcohol)6,24 were 
predominantly designed to ‘flag up’ patients at increased risk for bleeding to allow for 
correction of the reversible risk factors (e.g. uncontrolled hypertension, labile INR values, 
concomitant drugs, alcohol abuse, etc.)25 but were by no means intended to withhold or 
preclude OAC therapy.26 Importantly, the net clinical benefit of systemic anticoagulation, 
when balancing stroke risk reduction versus increased risk of bleeding, is still positive and 
even greater in patients at increased risk of bleeding.27 Therefore, once the reasons for 
interrupting OAC therapy have been corrected, a change from one anticoagulant to another 
may seem more reasonable than complete withdrawal of OAC therapy, even in patients who 
have survived major bleeds or those with prior intracranial hemorrhage.28,29 Similarly, in 
patients who have experienced an ischemic stroke despite being on OAC, a switch to a more 
effective anticoagulant to prevent a recurrent thromboembolic event, i.e. dabigatran 150 mg 
twice daily, could be considered.30   
 
Foregoing anticoagulation may also result from patient’s refusal to use OAC. However, this 
shared-decision making has to be based on detailed and clear explanation to a patient of their 
individual benefits and risks with OAC therapy.31  One recent study showed that 12% of AF 
patients would refuse OAC even if it was 100% effective in preventing strokes, while those 
who accepted anticoagulation were willing to accept 4.4 major bleeds to prevent one stroke.32 
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Limitations and Strengths 
A limitation of this study is that the analysis focused on the quantity but not quality of 
antithrombotic treatment. Despite having very precise data on various antithrombotics used as 
well as corrections made for antithrombotic drug uptake preceding the outcome events, 
neither INR nor TTR values were available. In addition, although the contraindications to, 
and reasons for patients declining, antithrombotic therapy were reported very precisely using 
Read codes, specific reasons for withholding or precluding OAC could not be identified. We 
could not establish the cause of death with certainty in 45 patients, as death certificates could 
not be retrieved. However, it is unlikely that any significant number of strokes were missed 
that way. It cannot be also excluded that some strokes were missed by being not coded, 
although this is also unlikely as stroke rates contribute to the stroke prevalence recording, 
which is linked to therapy reimbursement. Incorrect coding was addressed by a wide search 
of related conditions. 
Although the cohort was a broad patient representation from 11 GP practices serving the 
population of over 100,000 patients, it was confined to one UK region, and therefore the 
results may not be representative of other primary care populations in different regions. 
Unfortunately, data on socio-demographic characteristics were not available for the purpose 
of this analysis. However, in contrast to previous studies, we used very precise and robust 
criteria for study endpoints employed in randomized clinical trials, with stroke confirmed by 
cerebral imaging and every outcome event was manually adjudicated. The usefulness of the 
GRASP-AF tool employed for diagnostic and data collection purposes has been also 
previously confirmed.13  
Our definition of adherence to guidelines is different from previously published papers 
because we have analyzed the unselected cohort of consecutive all-comers and thus included 
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also those patients who declined OAC or had reported contraindications to therapy. Indeed, 
we aimed to assess the impact of guideline-adherence, rather than the specific impact of OAC 
therapy per se on clinical outcomes after completely excluding patients who denied treatment 
or had any contraindications. The results of the latter approach (broadly similar trends and 
showing even more pronounced effect of OAC on outcomes) have been summarized as a 
sensitivity analysis. 
 
Summary  
Despite a high thromboembolic risk profile, particularly amongst secondary prevention 
patients, only approximately 50% of AF patients in primary care are prescribed OAC in line 
with current guidelines. Guideline-adherent antithrombotic therapy significantly reduces the 
risk of stroke amongst primary prevention patients, but in those with prior stroke, there is also 
a significant reduction in both recurrent stroke and death rates. 
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Figure Legends 
Figure  1 Antithrombotic Treatment in Relation to Prior Stroke History 
OAC – oral anticoagulation 
 
Figure  2 Antithrombotic Treatment in Relation to Guideline-Adherence and Prior Stroke 
History 
Panel A Prior stroke history                                     Panel B No prior stroke history                
OAC – oral anticoagulation 
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Table 1 Baseline Characteristics Overall and in the Primary and Secondary Prevention 
Groups  
 
 
All Previous Stroke No Previous Stroke  
n (%) 2259 (100) 428 (18.9) 1831 (81.1) P-value 
Demographics     
Females 1041 (46.1) 193 (45.1) 848 (46.3) 0.68 
Age, years, mean [SD] 75.6 (12.2) 79.6 (9.6) 74.7 (12.6)  
<65 years 367 (16.2) 28 (6.5)  339 (18.5)   
65-74 years 554 (24.5) 93 (21.7)  461 (25.2)   
≥75 years 1338 (59.2) 307 (71.7) 1031 (56.3) <0.001 
Medical history     
Heart failure 514 (22.8) 106 (24.8) 408 (22.3) 0.27 
Hypertension 1404 (62.2) 305 (71.3) 1099 (60.0) 0.001 
Diabetes  490 (21.7) 120 (28.0) 370 (20.2) 0.001 
Vascular disease 389 (17.2) 97 (22.7) 292 (15.9) 0.001 
Acute myocardial 
infarction 
152 (6.7) 41 (9.6) 111 (6.1) 0.008 
Thromboembolic risk      
CHA2DS2-VASc, mean (SD) 3.5 (1.79) 5.5 (1.28) 3.0 (1.54)  
score=0 118 (5.2) 0 118 (6.4)  
score=1 206 (9.1) 0 206 (11.6)  
score≥2 1935 (85.7) 428 (100) 1507 (82.3) <0.001 
Antithrombotic treatment     
None 367 (16.2) 28 (6.5) 339 (18.5)  
Antiplatelets  812 (35.9) 136 (31.8) 676 (36.9)  
OAC 971 (43.0) 225 (52.6) 746 (40.7)  
OAC + antiplatelets 109 (4.8) 39 (9.1) 70 (3.8) <0.001 
Oral anticoagulation     
Contraindicated 187 (8.3) 59 (13.8) 128 (7.0) <0.001 
Declined 113 (5.0) 28 (6.5) 85 (4.6) 0.11 
Antithrombotic therapy     
Guideline adherent  1147 (50.8) 241 (56.3) 906 (49.5) 0.011 
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CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient 
ischemic attack (TIA), vascular disease, age 65-74 years, sex category (female); OAC, oral anticoagulant; SD,   
standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Over-treatment 296 (13.1) 81 (18.9) 215 (11.7) <0.001 
Under-treatment 816 (36.1) 106 (24.8) 710 (38.8) <0.001 
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Table 2 One-year Outcomes Overall and in the Primary and Secondary Prevention Groups  
 
Values in the same row not sharing the same subscript are significantly different at p<0.05  
* Confirmed by imaging (CT was predominantly used) 
ATT, antithrombotic treatment; CT, computer tomography; PE, pulmonary embolism; STE, systemic 
thromboembolism.  
 
 
 All 
 
Previous Stroke 
 
No Previous Stroke 
 
 
   
 n (%) 2259 (100.0) 428 (18.9) 1831 (81.1) P-value 
     
Recurrent/new stroke* 67 (3.0) 37 (8.6)  30 (1.6)  <0.001 
Ischemic 62 (2.7) 36 (8.4)  26 (1.4)   
Hemorrhagic  5 (0.2) 1 (0.2) a 4 (0.2) a  
     
Cause of death     
All-cause 214 (9.5) 42 (9.8) a 172 (9.4) a 0.79 
Cardiovascular     
Cardiac death 14 (0.6) 3 (0.7) a 11 (0.6) a  
Heart failure 24 (1.1) 3 (0.7) a 21 (1.1) a  
Stroke 11 (0.5) 3 (0.7) a 8 (0.4) a  
PE or STE 3 (0.1) 1 (0.2) a 2 (0.1) a  
Intracranial bleeding 5 (0.2) 1 (0.2) a 4 (0.2) a  
Non-cardiovascular     
Bleeding non-cerebral 3 (0.1) 2 (0.5)
 
 1 (0.1)
 
  
Cancer  42 (1.9) 4 (0.9) a 38 (2.1) a  
Other 67 (3.0) 16 (3.7) a 51 (2.8) a  
Unknown 45 (2.0) 9 (2.1) a 36 (2.0) a  
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Table 3 Event Rates at One-Year in Relation to Prior Stroke History, Thromboembolic Risk and Antithrombotic Guideline-Adherence 
 
 
 
 
 
 
 
 
 
Values in the same row not sharing the same subscript are significantly different at p<0.05  
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack (TIA), vascular disease, age 65-74 years, sex 
category (female); SD, standard deviation. 
 
n (%) 
 
Under-treatment 
 
Adherent treatment 
 
Over-treatment 
 
P-value 
     
     
Prior stroke history n=106  n=241  n=81   
CHA2DS2-VASc, mean (SD) 5.5 (1.40) 
a
 5.5 (1.26)
 a
 5.9 (1.11)
 a
 0.050 
Recurrent stroke 10 (9.4) a, b 13 (5.4) a 14 (17.3) b 0.011 
All-cause death 21 (19.8) 16 (6.6) a 5 (6.2) a 0.006 
     
No prior stroke n=710  n=906  n=215   
CHA2DS2-VASc, mean (SD) 3.1 (1.39)
 a
 3.2 (1.51)
 a
 2.4 (1.95)
 b
 <0.001 
New stroke 22 (3.1) 7 (0.8) a 1 (0.5) a 0.003 
All-cause death 94 (13.2) 65 (7.1) a 13 (6.0) a 0.003 
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Table 4 Multivariable Logistic Regression Analysis for New/Recurrent Stroke and Death in 
Relation to Prior Stroke History 
 
ATT, antithrombotic treatment; CI, confidence interval; OR, odds ratio; y, year 
 
 
 
 
 
New Stroke 
OR (95% CI) 
 
 
P value 
 
Death 
OR (95% CI) 
 
 
P value 
     
Prior stroke history     
Age (per 1 y increase) 1.00 (0.97-1.04) 0.83 1.08 (1.04-1.13) <0.001 
Female sex 1.32 (0.63-2.74) 0.46 1.02 (0.49-2.12) 0.96 
Hypertension 0.91 (0.43-1.95) 0.81 0.81 (0.38-1.72) 0.81 
Diabetes 1.72 (0.83-3.56) 0.14 2.21 (1.08-4.52) 0.03 
Heart failure 0.91 (0.39-2.12) 0.83 1.55 (0.73-3.30) 0.26 
Vascular disease 0.89 (0.38-2.10) 0.80 1.52 (0.70-3.28) 0.29 
ATT under-treatment 1.39 (0.58-3.30) 0.46 2.75 (1.33-5.69) 0.006 
ATT over-treatment 2.80 (1.25-6.27) 0.01 0.66 (0.23-1.89) 0.44 
     
No prior stroke     
Age (per 1 y increase) 1.07 (1.03-1.12) 0.002 1.11 (1.09-1.14) <0.001 
Female sex 2.29 (0.96-5.50) 0.06 1.32 (0.91-1.91) 0.15 
Hypertension 0.79 (0.36-1.73) 0.56 0.97 (0.67-1.41) 0.88 
Diabetes 2.11 (0.94-4.73) 0.07 1.31 (0.88-1.97) 0.19 
Heart failure 1.38 (0.60-3.15) 0.44 2.11 (1.46-3.05) <0.001 
Vascular disease 2.12 (0.94-4.78) 0.07 3.28 (2.25-4.78) <0.001 
ATT under-treatment 2.95 (1.26-6.90) 0.01 1.36 (0.94-1.97) 0.10 
ATT over-treatment 0.56 (0.07-4.57) 0.58 0.83 (0.43-1.61) 0.58 
